ProShare Advisors’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$646K Buy
9,997
+88
+0.9% +$6.2K ﹤0.01% 939
2025
Q4
$667K Buy
9,909
+767
+8% +$51.6K ﹤0.01% 983
2025
Q3
$670K Sell
9,142
-923
-9% -$61.3K ﹤0.01% 959
2025
Q2
$524K Sell
10,065
-27,918
-74% -$1.59M ﹤0.01% 1101
2025
Q1
$2.42M Sell
37,983
-9,131
-19% -$530K 0.01% 644
2024
Q4
$2.25M Buy
47,114
+10,531
+29% +$540K 0.01% 677
2024
Q3
$2.09M Buy
36,583
+5,325
+17% +$305K 0.01% 670
2024
Q2
$1.64M Sell
31,258
-7,404
-19% -$325K ﹤0.01% 690
2024
Q1
$1.57M Buy
38,662
+1,794
+5% +$67.3K ﹤0.01% 704
2023
Q4
$1.36M Buy
36,868
+4,249
+13% +$160K ﹤0.01% 698
2023
Q3
$1.25M Sell
32,619
-962
-3% -$39.4K ﹤0.01% 695
2023
Q2
$1.21M Buy
33,581
+477
+1% +$16.3K ﹤0.01% 697
2023
Q1
$1.26M Sell
33,104
-5,596
-14% -$262K ﹤0.01% 698
2022
Q4
$2.2M Buy
38,700
+2,448
+7% +$125K 0.01% 609
2022
Q3
$1.43M Buy
36,252
+423
+1% +$18.7K 0.01% 672
2022
Q2
$1.58M Sell
35,829
-18,389
-34% -$795K 0.01% 686
2022
Q1
$2.16M Sell
54,218
-12,097
-18% -$431K ﹤0.01% 705
2021
Q4
$2.67M Buy
66,315
+4,651
+8% +$174K 0.01% 704
2021
Q3
$2.51M Sell
61,664
-10,593
-15% -$443K 0.01% 669
2021
Q2
$3.28M Buy
72,257
+8,220
+13% +$364K 0.01% 597
2021
Q1
$2.67M Buy
64,037
+3,763
+6% +$172K 0.01% 617
2020
Q4
$2.57M Buy
60,274
+21,543
+56% +$774K 0.01% 575
2020
Q3
$1.02M Sell
38,731
-1,429
-4% -$39.8K ﹤0.01% 716
2020
Q2
$1.08M Buy
40,160
+12,116
+43% +$273K 0.01% 686
2020
Q1
$505K Sell
28,044
-23,049
-45% -$437K ﹤0.01% 730
2019
Q4
$906K Sell
51,093
-4,816
-9% -$83.4K ﹤0.01% 829
2019
Q3
$867K Buy
55,909
+221
+0.4% +$3.64K ﹤0.01% 794
2019
Q2
$957K Sell
55,688
-7,147
-11% -$115K 0.01% 771
2019
Q1
$1.01M Buy
62,835
+716
+1% +$11.6K 0.01% 754
2018
Q4
$909K Sell
62,119
-11,992
-16% -$191K 0.01% 736
2018
Q3
$1.35M Sell
74,111
-2,828
-4% -$49.5K 0.01% 702
2018
Q2
$1.3M Sell
76,939
-4,468
-5% -$84.5K 0.01% 741
2018
Q1
$1.59M Sell
81,407
-13,003
-14% -$252K 0.01% 669
2017
Q4
$1.91M Buy
94,410
+6,276
+7% +$115K 0.01% 621
2017
Q3
$1.53M Buy
88,134
+5,947
+7% +$80.6K 0.01% 623
2017
Q2
$1.05M Buy
82,187
+374
+0.5% +$5K 0.01% 721
2017
Q1
$1.06M Sell
81,813
-21,247
-21% -$269K 0.01% 731
2016
Q4
$1.02M Buy
103,060
+8,923
+9% +$97.7K 0.01% 766
2016
Q3
$1.14M Sell
94,137
-19,012
-17% -$194K 0.02% 642
2016
Q2
$976K Buy
113,149
+2,264
+2% +$22.3K 0.01% 723
2016
Q1
$1.05M Sell
110,885
-11,624
-9% -$109K 0.01% 681
2015
Q4
$2.12M Buy
122,509
+10,937
+10% +$174K 0.03% 486
2015
Q3
$1.5M Sell
111,572
-3,497
-3% -$70.2K 0.02% 558
2015
Q2
$2.6M Sell
115,069
-5,928
-5% -$104K 0.04% 427
2015
Q1
$1.73M Buy
120,997
+15,755
+15% +$227K 0.02% 610
2014
Q4
$1.02M Sell
105,242
-395
-0.4% -$3.51K 0.01% 842
2014
Q3
$961K Sell
105,637
-20,342
-16% -$194K 0.01% 1091
2014
Q2
$1.25M Sell
125,979
-66,586
-35% -$565K 0.02% 1057
2014
Q1
$2.45M Buy
192,565
+135,921
+240% +$2.02M 0.03% 626
2013
Q4
$849K Sell
56,644
-39,260
-41% -$505K 0.01% 1003
2013
Q3
$1.06M Buy
95,904
+15,925
+20% +$133K 0.03% 834
2013
Q2
$635K Buy
+79,979
New +$509K 0.01% 1139

Other funds holding HALO

ProShare Advisors's HALO Position: Q1 2026 in Review

ProShare Advisors increased its Halozyme (HALO) stake by 0.89% in Q1 2026, buying an estimated $6.2K and bringing the position to 9,997 shares worth $646K. The position accounts for ﹤0.01% of the portfolio, ranked #939.

ProShare Advisors first reported a position in HALO in Q2 2013 and has held it in 52 quarters since. The position peaked at $3.28M in Q2 2021. 635 funds tracked by Wall St. Rank hold HALO as of Q1 2026.

  • ProShare Advisors held 9,997 shares of Halozyme worth $646K as of Q1 2026.
  • ProShare Advisors bought 88 Halozyme shares in Q1 2026, an estimated $6.2K.
  • Halozyme made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #939 holding.
  • ProShare Advisors first reported a position in Halozyme in Q2 2013 and has held it in 52 quarters since.
  • ProShare Advisors's Halozyme position peaked at $3.28M in Q2 2021.
  • 635 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.